Farajallah Awny Samaan Botros — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Farajallah Awny Samaan Botros has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
Profile
Farajallah Awny Samaan Botros is listed in SEC filings as the Chief Medical Officer of Takeda Pharmaceutical Co Ltd as of July 6, 2026. In this capacity, he would be responsible for medical strategy, clinical development oversight, global medical affairs, and patient safety initiatives at Takeda. The available SEC-context information does not provide details on his educational background or prior career history. There is no explicit information in the provided context indicating he is deceased; he is presented as an active executive in the filing context.
Role
Chief Medical Officer
Notability
65/100
Board memberships
Takeda Pharmaceutical Co Ltd
Awards & honors
Oversees medical strategy and clinical development activities for Takeda
Manages global medical affairs and patient safety initiatives (as inferred from CMO role)
Farajallah Awny Samaan Botros is listed in SEC filings as the Chief Medical Officer of Takeda Pharmaceutical Co Ltd as of July 6, 2026. In this capacity, he would be responsible for medical strategy, clinical development oversight, global medical affairs, and patient safety initiatives at Takeda. The available SEC-context information does not provide details on his educational …
How many SEC Form 4 filings has Farajallah Awny Samaan Botros submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Farajallah Awny Samaan Botros's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
